Natera Eyes Massive New Cancer Market; In Buy Zone With Q2 Report Due

Natera (NTRA) has seen buyers flood in after the cancer test maker tapped a new market following regulatory approval in Japan in June. The company now faces a test from investors scoring its financial results, making Natera the IBD 50 Growth Stock To Watch for Thursday. Second-quarter results for Natera are due at market close Thursday. The stock holds a…